NaNots are a new nano-medical platform consisting of in vivo “extractors” that deplete from blood specific molecular signals or signal inhibitors that drive or enable disease progression.
Our first NaNot – which has shown efficacy in a mouse model of Triple Negative Breast Cancer – is an extractor of one class of tumor-generated immune inhibitor. We have also successfully tested a NaNot against a major inflammatory cytokine driving multiple autoimmune diseases.
NaNots are based on several interrelated disciplines, including cell signaling, oncology, immunology, biochemistry and nano engineering, among others. Our team is interdisciplinary and is guided by world-class advisors. We build on thousands of published studies and are also running our own target analyses and clinical studies in addition to our core engineering program.
In this section, you can learn more about NaNots, including how they compare with antibody (Ab) drugs. If you have access to the confidential sections of our site, you can also learn more about the targets that NaNots can extract and which diseases they can potentially treat.
What’s a NaNot?
NaNots are injectable nanoparticles that “extract” specific aberrant cell signals or signal inhibitors circulating in blood, which drive virtually all non-genetic diseases, including solid tumor cancers and autoimmune diseases.
NaNots can be “programmed” to treat different diseases by changing the signals/inhibitors they capture.
NaNots do not target cells of any type and in fact are shielded against ALL cell membrane interactions – greatly reducing or eliminating unintended effects
NaNots are fully biocompatible; they are injected like a drug and cleared by macrophages after they capture their targets.
NaNots were invented by founders of NaNotics, LLC, based in Mill Valley, CA and London, UK, with subsidiaries in Singapore and Dublin, Ireland. The company has raised $8.75m USD to date in Seed/Series A/A2 rounds, and has received 3 broad patents to date, with 7 more patent families pending.
Advantages of NaNots vs Ab Drugs
- Any disease driven by cell signals or inhibitors – including many “undruggable” targets – can potentially be treated by NaNots
- Extractable targets driving multiple types of cancer, autoimmune disease and infectious disease have been identified
- The Company is planning a factory for designing, testing & fabricating new NaNots every few months
- The NaNot platform has utility for healthy aging as well via senolytic NaNots under development
- Rapid action: >90% target depletion in <5 minutes, leading to rapid clinical response
- No tissue targeting required – targets find NaNots in blood via diffusion (avoids prime reason prior nanomedicines have failed)
- No Loss of Response (LOR) – NaNot shielding prevents interrogation of capture agents by B cells leading to formation of anti-drug antibodies – a common problem with Ab drugs
- Detailed efficacy data available under NDA
- Targets only soluble forms of signal / inhibitor molecules – avoiding all cell membrane interactions, the cause of many drug side effects
- No stimulation of immune function required – immune efficacy can be enhanced just by extracting inhibitors
- NaNots are produced in a GMP grade facility using materials that the FDA already regards as safe
- NaNots do not cross-react – multiple NaNots can be administered to same patient at same time
- NaNots have been shown to be safe in mice even at 100x anticipated clinical dosing
- Targets can be quantified in each patient in advance of treatment, enabling precise dosing of correct NaNot types
- Target quantification enables personalized medicine without costly personalized therapeutics (unlike cell therapies)
- Temporal precision of nano-extraction allows previously unfeasible sequential therapeutics
– e.g. sepsis, which has multiple phases that each require distinct therapeutic intervention
Development Time & Cost (Pre-Clinical)
The NaNot development process is significantly faster and cheaper than the process of developing antibody drugs. The problem with many drugs is that their targets have both pathogenic and homeostatic forms; drug designers must iterate repeatedly between drug design and animal testing, before arriving at a favorable balance of efficacy and safety. NaNot engineers, by comparison, can focus on efficacy during development because NaNot capture agents are sequestered behind shields that block cellular interactions and associated side effects. We can currently design new NaNots and test in animals in less than 6 months – which we expect to trim by half within 2 years.